Share Price and Basic Stock Data
Last Updated: February 12, 2026, 10:06 pm
| PEG Ratio | 2.07 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Colinz Laboratories Ltd operates in the pharmaceuticals sector and has reported a current market capitalization of ₹6.86 Cr, with a share price of ₹54.5. The company’s sales figures have shown fluctuations over the last few quarters, with total sales reaching ₹1.68 Cr in December 2022, rising to ₹1.90 Cr in June 2023, and then declining to ₹1.79 Cr in September 2023. The figures indicate a slight recovery with ₹1.71 Cr reported in December 2023. Annual sales have not shown significant growth, with a total of ₹7.15 Cr reported for FY 2023, a marginal increase from ₹6.97 Cr in FY 2022. However, the trailing twelve months (TTM) revenue stands at ₹5.88 Cr, suggesting a decline in sales momentum. The company’s ability to maintain revenue amidst market challenges is critical for its future growth, especially as it operates in a competitive landscape with varying demand for pharmaceutical products.
Profitability and Efficiency Metrics
Colinz Laboratories has reported a net profit of ₹0.46 Cr for FY 2023, reflecting an increase from ₹0.34 Cr in FY 2022. The operating profit margin (OPM) stood at 6.99%, indicating a stable profitability structure, although it remains below the sector average, which typically ranges from 15% to 20%. The company has maintained a reasonable interest coverage ratio (ICR) of 18.70x, showcasing its ability to meet interest obligations comfortably. However, the return on equity (ROE) was recorded at 5.43%, which is relatively low compared to industry standards, suggesting limited effectiveness in generating returns for shareholders. The cash conversion cycle (CCC) of 78.81 days indicates a moderate efficiency in managing working capital, which is crucial for maintaining liquidity amid fluctuating sales. Overall, while profitability metrics show some positive trends, efficiency ratios highlight areas that require attention to enhance operational performance.
Balance Sheet Strength and Financial Ratios
Colinz Laboratories demonstrates a solid balance sheet with total reserves of ₹7.36 Cr and minimal borrowings of ₹0.66 Cr, reflecting a conservative capital structure. The total debt-to-equity ratio stands at a mere 0.06, indicating low financial leverage, which is advantageous in times of economic uncertainty. The company’s current ratio is reported at 4.17, significantly above the typical threshold of 1.5, suggesting that it has ample liquidity to cover short-term liabilities. However, the price-to-book value (P/BV) ratio is noted at 1.93x, which is relatively high compared to industry norms, potentially indicating overvaluation. The return on capital employed (ROCE) was recorded at 6.72%, which, while steady, is below the sector average of around 10% to 15%. This ratio indicates that while the company is using its capital effectively, there is room for improvement in generating higher returns from its capital investments.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Colinz Laboratories reveals a strong promoter presence, with promoters holding 66% of the equity, which demonstrates significant insider confidence in the company’s prospects. However, the absence of Foreign Institutional Investors (FIIs) and the very low stake of Domestic Institutional Investors (DIIs) at 0% suggests a lack of institutional interest, which could impact the stock’s liquidity and appeal to larger investors. The public shareholding stood at 33.99%, reflecting a stable base of retail investors, which is crucial for maintaining stock stability. The number of shareholders has increased from 2,863 in December 2022 to 3,272 by September 2025, indicating growing interest among retail investors. This upward trend in retail participation may enhance market confidence in the company, provided it continues to deliver on its financial performance.
Outlook, Risks, and Final Insight
The outlook for Colinz Laboratories hinges on its ability to improve profitability and operational efficiency. While the company has shown resilience in maintaining its sales levels amidst challenges, its low ROE and OPM indicate areas needing enhancement. Risks include potential fluctuations in raw material costs and competitive pressures that may affect margins. Additionally, the lack of institutional investment could hinder stock performance and market perception. On the positive side, the strong promoter holding and low debt levels provide a foundation for stability and strategic growth. Should Colinz Laboratories enhance its operational efficiencies and capitalize on market opportunities, it could improve its profitability metrics significantly. Conversely, failure to address its efficiency issues may limit growth potential and shareholder returns in the long run.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 158/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,451 Cr. | 319 | 479/192 | 72.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 30.6 Cr. | 41.3 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 82.8 Cr. | 56.5 | 56.7/17.0 | 197 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,994.39 Cr | 1,109.18 | 54.25 | 201.93 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.68 | 1.72 | 1.90 | 1.79 | 1.71 | 1.63 | 1.75 | 1.86 | 1.47 | 1.45 | 1.57 | 1.39 | 1.43 |
| Expenses | 1.55 | 1.56 | 1.74 | 1.67 | 1.57 | 1.51 | 1.59 | 1.69 | 1.40 | 1.35 | 1.44 | 1.31 | 1.33 |
| Operating Profit | 0.13 | 0.16 | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 | 0.17 | 0.07 | 0.10 | 0.13 | 0.08 | 0.10 |
| OPM % | 7.74% | 9.30% | 8.42% | 6.70% | 8.19% | 7.36% | 9.14% | 9.14% | 4.76% | 6.90% | 8.28% | 5.76% | 6.99% |
| Other Income | 0.04 | 0.04 | 0.04 | 0.08 | 0.05 | 0.11 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.16 | 0.08 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 |
| Profit before tax | 0.13 | 0.16 | 0.16 | 0.16 | 0.15 | 0.19 | 0.19 | 0.21 | 0.11 | 0.13 | 0.16 | 0.19 | 0.13 |
| Tax % | 23.08% | 18.75% | 18.75% | 25.00% | 26.67% | 31.58% | 26.32% | 23.81% | 45.45% | -23.08% | 25.00% | 26.32% | 30.77% |
| Net Profit | 0.10 | 0.13 | 0.12 | 0.12 | 0.11 | 0.14 | 0.14 | 0.16 | 0.05 | 0.15 | 0.12 | 0.14 | 0.08 |
| EPS in Rs | 0.40 | 0.52 | 0.48 | 0.48 | 0.44 | 0.56 | 0.56 | 0.64 | 0.20 | 0.60 | 0.48 | 0.56 | 0.32 |
Last Updated: February 2, 2026, 1:46 pm
Below is a detailed analysis of the quarterly data for Colinz Laboratories Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 1.43 Cr.. The value appears strong and on an upward trend. It has increased from 1.39 Cr. (Sep 2025) to 1.43 Cr., marking an increase of 0.04 Cr..
- For Expenses, as of Dec 2025, the value is 1.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.31 Cr. (Sep 2025) to 1.33 Cr., marking an increase of 0.02 Cr..
- For Operating Profit, as of Dec 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Sep 2025) to 0.10 Cr., marking an increase of 0.02 Cr..
- For OPM %, as of Dec 2025, the value is 6.99%. The value appears strong and on an upward trend. It has increased from 5.76% (Sep 2025) to 6.99%, marking an increase of 1.23%.
- For Other Income, as of Dec 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 0.16 Cr. (Sep 2025) to 0.08 Cr., marking a decrease of 0.08 Cr..
- For Interest, as of Dec 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.01 Cr..
- For Depreciation, as of Dec 2025, the value is 0.04 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.04 Cr..
- For Profit before tax, as of Dec 2025, the value is 0.13 Cr.. The value appears to be declining and may need further review. It has decreased from 0.19 Cr. (Sep 2025) to 0.13 Cr., marking a decrease of 0.06 Cr..
- For Tax %, as of Dec 2025, the value is 30.77%. The value appears to be increasing, which may not be favorable. It has increased from 26.32% (Sep 2025) to 30.77%, marking an increase of 4.45%.
- For Net Profit, as of Dec 2025, the value is 0.08 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Sep 2025) to 0.08 Cr., marking a decrease of 0.06 Cr..
- For EPS in Rs, as of Dec 2025, the value is 0.32. The value appears to be declining and may need further review. It has decreased from 0.56 (Sep 2025) to 0.32, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 7.15 | 7.03 | 6.53 | 5.88 |
| Expenses | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.52 | 6.49 | 6.04 | 5.50 |
| Operating Profit | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.63 | 0.54 | 0.49 | 0.38 |
| OPM % | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.81% | 7.68% | 7.50% | 6.46% |
| Other Income | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.15 | 0.28 | 0.30 | 0.40 |
| Interest | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 | 0.04 | 0.04 | 0.05 |
| Depreciation | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.13 | 0.13 | 0.13 | 0.14 |
| Profit before tax | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.60 | 0.65 | 0.62 | 0.59 |
| Tax % | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | 23.33% | 26.15% | 20.97% | |
| Net Profit | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.46 | 0.49 | 0.50 | 0.46 |
| EPS in Rs | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 1.01 | 1.07 | 1.09 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 42.86% | -10.00% | 55.56% | 64.29% | -47.83% | 8.33% | 61.54% | 61.90% | 35.29% | 6.52% | 2.04% |
| Change in YoY Net Profit Growth (%) | 0.00% | -52.86% | 65.56% | 8.73% | -112.11% | 56.16% | 53.21% | 0.37% | -26.61% | -28.77% | -4.48% |
Colinz Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -2% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 31% |
| 3 Years: | 14% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 40% |
| 3 Years: | 3% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 10, 2025, 4:05 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | 2.52 | 2.52 | 2.52 |
| Reserves | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.62 | 6.43 | 6.96 | 7.36 |
| Borrowings | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.27 | 0.57 | 0.64 | 0.66 |
| Other Liabilities | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 1.82 | 1.84 | 1.70 | 1.59 |
| Total Liabilities | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
| Fixed Assets | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.71 | 1.58 | 1.70 | 1.62 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.66 | 1.02 | 1.04 | 1.21 |
| Other Assets | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 7.86 | 8.76 | 9.08 | 9.30 |
| Total Assets | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.23 | 11.36 | 11.82 | 12.13 |
Below is a detailed analysis of the balance sheet data for Colinz Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 2.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.52 Cr..
- For Reserves, as of Sep 2025, the value is 7.36 Cr.. The value appears strong and on an upward trend. It has increased from 6.96 Cr. (Mar 2025) to 7.36 Cr., marking an increase of 0.40 Cr..
- For Borrowings, as of Sep 2025, the value is 0.66 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.64 Cr. (Mar 2025) to 0.66 Cr., marking an increase of 0.02 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.59 Cr.. The value appears to be improving (decreasing). It has decreased from 1.70 Cr. (Mar 2025) to 1.59 Cr., marking a decrease of 0.11 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1.62 Cr.. The value appears to be declining and may need further review. It has decreased from 1.70 Cr. (Mar 2025) to 1.62 Cr., marking a decrease of 0.08 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 1.21 Cr.. The value appears strong and on an upward trend. It has increased from 1.04 Cr. (Mar 2025) to 1.21 Cr., marking an increase of 0.17 Cr..
- For Other Assets, as of Sep 2025, the value is 9.30 Cr.. The value appears strong and on an upward trend. It has increased from 9.08 Cr. (Mar 2025) to 9.30 Cr., marking an increase of 0.22 Cr..
- For Total Assets, as of Sep 2025, the value is 12.13 Cr.. The value appears strong and on an upward trend. It has increased from 11.82 Cr. (Mar 2025) to 12.13 Cr., marking an increase of 0.31 Cr..
Notably, the Reserves (7.36 Cr.) exceed the Borrowings (0.66 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.54 | -2.07 | -1.35 | -0.35 | -0.07 | -0.33 | -0.07 | -0.65 | 0.11 | 0.36 | -0.03 | -0.15 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 | 57.69 | 44.65 | 36.89 |
| Inventory Days | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 | 149.17 | 134.31 | 136.22 |
| Days Payable | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 | 103.15 | 94.81 | 94.31 |
| Cash Conversion Cycle | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 | 103.71 | 84.15 | 78.81 |
| Working Capital Days | 89.65 | 110.24 | 100.04 | 71.19 | 72.72 | 89.45 | 79.01 | 0.00 | 9.95 | 11.23 | -22.84 | 72.66 |
| ROCE % | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% | 8.08% | 7.70% | 6.72% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Diluted EPS (Rs.) | 1.97 | 1.93 | 1.82 | 0.74 | 0.99 |
| Cash EPS (Rs.) | 2.49 | 2.45 | 2.33 | 1.52 | 0.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 37.61 | 35.52 | 32.31 | 21.68 | 20.57 |
| Revenue From Operations / Share (Rs.) | 25.91 | 27.91 | 28.40 | 19.67 | 17.37 |
| PBDIT / Share (Rs.) | 3.15 | 3.25 | 3.10 | 2.13 | 0.93 |
| PBIT / Share (Rs.) | 2.63 | 2.73 | 2.59 | 1.57 | 0.93 |
| PBT / Share (Rs.) | 2.46 | 2.58 | 2.38 | 1.35 | 0.69 |
| Net Profit / Share (Rs.) | 1.97 | 1.93 | 1.81 | 0.95 | 0.58 |
| PBDIT Margin (%) | 12.14 | 11.63 | 10.91 | 10.85 | 5.38 |
| PBIT Margin (%) | 10.13 | 9.78 | 9.11 | 7.96 | 5.38 |
| PBT Margin (%) | 9.48 | 9.25 | 8.38 | 6.88 | 3.98 |
| Net Profit Margin (%) | 7.60 | 6.92 | 6.39 | 4.86 | 3.37 |
| Return on Networth / Equity (%) | 5.24 | 5.43 | 5.61 | 4.41 | 2.84 |
| Return on Capital Employeed (%) | 6.85 | 7.49 | 7.81 | 6.99 | 4.41 |
| Return On Assets (%) | 4.20 | 4.28 | 4.47 | 3.41 | 2.05 |
| Total Debt / Equity (X) | 0.06 | 0.06 | 0.03 | 0.06 | 0.13 |
| Asset Turnover Ratio (%) | 0.56 | 0.65 | 0.70 | 0.69 | 0.65 |
| Current Ratio (X) | 4.17 | 4.00 | 4.15 | 3.72 | 2.82 |
| Quick Ratio (X) | 3.81 | 3.62 | 3.66 | 3.26 | 2.34 |
| Inventory Turnover Ratio (X) | 8.02 | 0.56 | 0.66 | 0.55 | 0.37 |
| Interest Coverage Ratio (X) | 18.70 | 21.98 | 14.93 | 10.03 | 3.83 |
| Interest Coverage Ratio (Post Tax) (X) | 12.71 | 14.08 | 9.75 | 5.49 | 3.40 |
| Enterprise Value (Cr.) | 13.34 | 3.03 | 3.36 | 3.63 | -0.99 |
| EV / Net Operating Revenue (X) | 2.04 | 0.43 | 0.46 | 0.52 | -0.16 |
| EV / EBITDA (X) | 16.82 | 3.70 | 4.30 | 4.79 | -3.00 |
| MarketCap / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| Price / BV (X) | 1.93 | 1.06 | 1.08 | 1.09 | 0.36 |
| Price / Net Operating Revenue (X) | 2.80 | 1.35 | 1.23 | 1.20 | 0.43 |
| EarningsYield | 0.02 | 0.05 | 0.05 | 0.04 | 0.07 |
After reviewing the key financial ratios for Colinz Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.45 (Mar 24) to 2.49, marking an increase of 0.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 37.61. It has increased from 35.52 (Mar 24) to 37.61, marking an increase of 2.09.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 25.91. It has decreased from 27.91 (Mar 24) to 25.91, marking a decrease of 2.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.15. This value is within the healthy range. It has decreased from 3.25 (Mar 24) to 3.15, marking a decrease of 0.10.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.63. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.63, marking a decrease of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 2.58 (Mar 24) to 2.46, marking a decrease of 0.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from 1.93 (Mar 24) to 1.97, marking an increase of 0.04.
- For PBDIT Margin (%), as of Mar 25, the value is 12.14. This value is within the healthy range. It has increased from 11.63 (Mar 24) to 12.14, marking an increase of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has increased from 9.78 (Mar 24) to 10.13, marking an increase of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 10. It has increased from 9.25 (Mar 24) to 9.48, marking an increase of 0.23.
- For Net Profit Margin (%), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 7.60, marking an increase of 0.68.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 5.43 (Mar 24) to 5.24, marking a decrease of 0.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.85. This value is below the healthy minimum of 10. It has decreased from 7.49 (Mar 24) to 6.85, marking a decrease of 0.64.
- For Return On Assets (%), as of Mar 25, the value is 4.20. This value is below the healthy minimum of 5. It has decreased from 4.28 (Mar 24) to 4.20, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.65 (Mar 24) to 0.56, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 4.17. This value exceeds the healthy maximum of 3. It has increased from 4.00 (Mar 24) to 4.17, marking an increase of 0.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.81. This value exceeds the healthy maximum of 2. It has increased from 3.62 (Mar 24) to 3.81, marking an increase of 0.19.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.02. This value exceeds the healthy maximum of 8. It has increased from 0.56 (Mar 24) to 8.02, marking an increase of 7.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.70. This value is within the healthy range. It has decreased from 21.98 (Mar 24) to 18.70, marking a decrease of 3.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.71. This value is within the healthy range. It has decreased from 14.08 (Mar 24) to 12.71, marking a decrease of 1.37.
- For Enterprise Value (Cr.), as of Mar 25, the value is 13.34. It has increased from 3.03 (Mar 24) to 13.34, marking an increase of 10.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.04. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 2.04, marking an increase of 1.61.
- For EV / EBITDA (X), as of Mar 25, the value is 16.82. This value exceeds the healthy maximum of 15. It has increased from 3.70 (Mar 24) to 16.82, marking an increase of 13.12.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For Price / BV (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.93, marking an increase of 0.87.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 1.35 (Mar 24) to 2.80, marking an increase of 1.45.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Colinz Laboratories Ltd:
- Net Profit Margin: 7.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.85% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.71
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 13.3 (Industry average Stock P/E: 54.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-101, Pratik Ind.Estate, Mulund-Goregaon Link Road, Mumbai Maharashtra 400078 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. N K Menon | Whole Time Director |
| Mr. A Krishna Kumar | Independent Director |
| Dr. Mani L S | Non Executive Director |
| Mr. Bhavik Ashokkumar Shah | Independent Director |
| Mr. Baptist Bernard Dias | Independent Director |
FAQ
What is the intrinsic value of Colinz Laboratories Ltd?
Colinz Laboratories Ltd's intrinsic value (as of 13 February 2026) is ₹24.58 which is 52.46% lower the current market price of ₹51.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6.52 Cr. market cap, FY2025-2026 high/low of ₹88.7/36.1, reserves of ₹7.36 Cr, and liabilities of ₹12.13 Cr.
What is the Market Cap of Colinz Laboratories Ltd?
The Market Cap of Colinz Laboratories Ltd is 6.52 Cr..
What is the current Stock Price of Colinz Laboratories Ltd as on 13 February 2026?
The current stock price of Colinz Laboratories Ltd as on 13 February 2026 is ₹51.7.
What is the High / Low of Colinz Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Colinz Laboratories Ltd stocks is ₹88.7/36.1.
What is the Stock P/E of Colinz Laboratories Ltd?
The Stock P/E of Colinz Laboratories Ltd is 13.3.
What is the Book Value of Colinz Laboratories Ltd?
The Book Value of Colinz Laboratories Ltd is 39.2.
What is the Dividend Yield of Colinz Laboratories Ltd?
The Dividend Yield of Colinz Laboratories Ltd is 0.00 %.
What is the ROCE of Colinz Laboratories Ltd?
The ROCE of Colinz Laboratories Ltd is 6.72 %.
What is the ROE of Colinz Laboratories Ltd?
The ROE of Colinz Laboratories Ltd is 5.43 %.
What is the Face Value of Colinz Laboratories Ltd?
The Face Value of Colinz Laboratories Ltd is 10.0.